Patent intelligence · US
US 11058664
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
Patent details — US 11058664
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 13, 2021
- Expiration
- Jul 8, 2041
- Applicant
- Provectus Pharmatech, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/343, A61K31/352, A61K31/365
Quick answer
US 11058664 (In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Jul 13, 2021. Expires Jul 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/343, A61K31/352, A61K31/365, A61K31/4745, A61K31/475
More from Provectus Pharmatech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 11058664?
US 11058664 (In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Jul 13, 2021. Expires Jul 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11058664?
Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 11058664 expire?
Our index shows an expiration date of Jul 8, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.